8.4 Biologic Response Modifiers
3 min read•june 18, 2024
are game-changers in cancer treatment. These powerful agents boost the 's ability to fight cancer, infections, and other diseases. From to , they offer a range of options for enhancing the body's natural defenses.
Understanding how these modifiers work is crucial for nurses. They stimulate immune cells, target cancer antigens, and regulate cell growth. Side effects can be significant, ranging from flu-like symptoms to autoimmune reactions, so careful monitoring and patient education are essential for successful treatment.
Overview of Biologic Response Modifiers in Cancer Treatment
Key features of biologic response modifiers
Top images from around the web for Key features of biologic response modifiers
Frontiers | Exosomes and Their Role in Cancer Progression View original
Is this image relevant?
Frontiers | Diversity of immune checkpoints in cancer immunotherapy View original
Is this image relevant?
Frontiers | Curcumin as an Adjuvant to Cancer Immunotherapy View original
Is this image relevant?
Frontiers | Exosomes and Their Role in Cancer Progression View original
Is this image relevant?
Frontiers | Diversity of immune checkpoints in cancer immunotherapy View original
Is this image relevant?
1 of 3
Top images from around the web for Key features of biologic response modifiers
Frontiers | Exosomes and Their Role in Cancer Progression View original
Is this image relevant?
Frontiers | Diversity of immune checkpoints in cancer immunotherapy View original
Is this image relevant?
Frontiers | Curcumin as an Adjuvant to Cancer Immunotherapy View original
Is this image relevant?
Frontiers | Exosomes and Their Role in Cancer Progression View original
Is this image relevant?
Frontiers | Diversity of immune checkpoints in cancer immunotherapy View original
Is this image relevant?
1 of 3
- Stimulate or restore immune system's ability to fight cancer, infections, and other diseases
- Derived from natural sources (human, animal, or microorganism proteins) or produced in laboratory
- Types used in cancer treatment:
- Interferons () boost immune response and inhibit cancer cell growth
- () regulate immune cell growth and differentiation
- () stimulate production of blood cells in bone marrow
- () target specific antigens on cancer cells
- stimulate immune recognition and attack of cancer cells
- block proteins that prevent immune cells from attacking cancer cells
- Can be used alone or in combination with other cancer treatments (chemotherapy, radiation therapy, or surgery)
Mechanism and side effects of modifiers
- Interferons (IFNs) and Interleukins (ILs):
- Stimulate immune system to attack cancer cells and enhance immune cell function
- Regulate immune cell growth and differentiation
- Side effects: flu-like symptoms, fatigue, depression, liver dysfunction
- Colony-stimulating factors (CSFs):
- Stimulate blood cell production in bone marrow
- Help recover from chemotherapy-induced and
- Side effects: bone pain, fever, allergic reactions
- Monoclonal antibodies (mAbs):
- Target specific antigens on cancer cells leading to their destruction
- Used for , , or drug delivery
- Side effects: , fever, chills, weakness, nausea, rashes
- Cancer vaccines:
- Stimulate immune recognition and attack of cancer cells
- Preventive () or therapeutic ( for prostate cancer)
- Side effects: injection site reactions, flu-like symptoms, autoimmune reactions
- Immune checkpoint inhibitors:
- Block proteins that prevent immune cells from attacking cancer cells
- Examples: (), /PD-L1 (, )
- Side effects: autoimmune reactions (, , )
Immune System Components and Their Roles
- : Signaling molecules that regulate immune responses and cell communication
- : Crucial for cell-mediated immunity and destroying infected or cancerous cells
- : Produce antibodies for humoral immunity and act as
- : Provide rapid responses against virus-infected cells and tumors
- Antigen-presenting cells: Process and present antigens to activate T cells
Nursing Considerations and Patient Education
Nursing considerations for modifier administration
- Assess patient's health status and immune function before initiating therapy
- Monitor patients closely for signs and symptoms of adverse reactions during and after administration
- Manage side effects promptly with appropriate interventions (antipyretics, analgesics)
- Observe for signs of infusion reactions (dyspnea, hypotension, urticaria) and be prepared to manage
- Ensure proper storage, preparation, and administration of BRMs according to manufacturer's instructions
- Collaborate with multidisciplinary team to provide comprehensive care and support to patients receiving BRMs
Patient education for modifier recipients
- Educate patients about purpose, benefits, and potential risks of BRM therapy
- Instruct patients to report signs or symptoms of adverse reactions (fever, chills, rash, difficulty breathing)
- Encourage healthy lifestyle (balanced diet, regular exercise, adequate rest)
- Advise patients to avoid close contact with people who have infections or recent live virus vaccinations
- Emphasize importance of adhering to treatment schedule and attending follow-up appointments
- Provide emotional support and resources for coping with physical and psychological challenges of cancer treatment
- Inform patients about potential long-term effects of BRM therapy and need for ongoing monitoring and follow-up care
- Explain the risk of developing as a potential side effect of some biologic response modifiers
Key Terms to Review (54)
Adaptive immune system: The adaptive immune system is a specialized part of the immune system that targets specific pathogens with high precision. It has memory capabilities, allowing it to respond more effectively upon subsequent exposures to the same pathogen.
Anaphylaxis: Anaphylaxis is a severe, life-threatening allergic reaction that can occur rapidly and requires immediate medical attention. It involves multiple organ systems and can lead to shock and death if not treated promptly.
Anaphylaxis: Anaphylaxis is a severe, whole-body allergic reaction that can be life-threatening. It occurs when the immune system overreacts to an allergen, triggering the rapid release of chemicals that cause widespread inflammation and impair breathing and blood circulation.
Anemia: Anemia is a condition characterized by a decrease in the number or quality of red blood cells, leading to a reduced ability to transport oxygen throughout the body. This can have significant implications in various medical contexts, including intravenous fluid therapy, total parenteral nutrition, blood products, immunosuppressants, chemotherapeutic drugs, biologic response modifiers, and oxygenation and gas exchange.
Anti-CTLA-4: Anti-CTLA-4 is a type of immunotherapy that works by blocking the CTLA-4 protein, which is a checkpoint receptor that normally acts to suppress the immune system. By inhibiting CTLA-4, anti-CTLA-4 therapies enhance the body's immune response against cancer cells, making them an important class of biologic response modifiers.
Anti-PD-1: Anti-PD-1 is a type of immunotherapy that targets the programmed cell death-1 (PD-1) receptor, a key regulator of the immune system. By blocking the interaction between PD-1 and its ligands, anti-PD-1 therapies reinvigorate the body's immune response against cancer cells.
Anti-PD-L1: Anti-PD-L1 is a type of immunotherapy that targets the programmed death-ligand 1 (PD-L1) protein, which is often expressed on the surface of cancer cells. By blocking the interaction between PD-L1 and its receptor PD-1 on T cells, anti-PD-L1 therapy helps the immune system recognize and attack cancer cells more effectively.
Antigen-Presenting Cells: Antigen-presenting cells (APCs) are a diverse group of immune cells that play a crucial role in the activation and regulation of the adaptive immune response. These specialized cells are responsible for capturing, processing, and presenting foreign antigens to T lymphocytes, initiating the adaptive immune cascade.
Atezolizumab: Atezolizumab is a monoclonal antibody used as an immune checkpoint inhibitor in cancer therapy. It targets and inhibits PD-L1, enhancing the body's immune response against tumors.
Autoimmune Disorders: Autoimmune disorders are a group of conditions in which the body's immune system mistakenly attacks and damages its own healthy tissues and cells. This aberrant immune response can lead to a wide range of chronic and debilitating health issues. In the context of 8.4 Biologic Response Modifiers, autoimmune disorders represent a key target for these therapeutic agents, which aim to modulate the dysregulated immune system.
B cells: B cells, also known as B lymphocytes, are a type of white blood cell that play a crucial role in the adaptive immune response. They are responsible for the production of antibodies, which help neutralize and eliminate pathogens, and also assist in the activation of other immune cells.
Biologic Response Modifiers: Biologic response modifiers are a class of drugs that work by modulating the body's immune system to fight disease. They are used to treat a variety of conditions, including cancer, autoimmune disorders, and infectious diseases, by enhancing, suppressing, or redirecting the natural immune response.
Cancer Vaccines: Cancer vaccines are a type of immunotherapy that stimulate the body's immune system to recognize and attack cancer cells. They work by exposing the immune system to specific molecules or antigens found on cancer cells, prompting the immune system to mount a targeted response against those cancer cells.
Colitis: Colitis is a type of inflammatory bowel disease (IBD) characterized by inflammation of the colon, or large intestine. It can cause symptoms such as abdominal pain, diarrhea, and rectal bleeding. Colitis is an important consideration in the context of biologic response modifiers, as certain immunosuppressive therapies can impact the management and progression of this condition.
Colony-Stimulating Factors: Colony-stimulating factors (CSFs) are a group of glycoproteins that stimulate the production, differentiation, and maturation of various blood cell types, particularly white blood cells, from hematopoietic stem cells. They play a crucial role in the regulation of the immune system and inflammatory responses within the context of Biologic Response Modifiers.
CSFs: CSFs, or colony-stimulating factors, are a group of glycoproteins that stimulate the production, differentiation, and maturation of various blood cells, particularly white blood cells, in the bone marrow. They play a crucial role in the body's biologic response to infections, inflammation, and other medical conditions.
Cytokines: Cytokines are small signaling proteins secreted by various cells in the body, particularly immune cells, that play a crucial role in regulating the immune response, inflammation, and other physiological processes. They act as chemical messengers, allowing cells to communicate with each other and coordinate their activities.
Durvalumab: Durvalumab is an immune checkpoint inhibitor that targets the PD-L1 protein, enhancing the body's immune response against cancer cells. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma.
Endocrinopathies: Endocrinopathies are disorders or diseases that affect the endocrine system, which is responsible for producing and regulating hormones in the body. These conditions can lead to imbalances or dysfunctions in hormone production, secretion, and regulation, impacting various physiological processes and overall health.
Erlotinib: Erlotinib is a tyrosine kinase inhibitor used to treat non-small cell lung cancer and pancreatic cancer. It works by inhibiting the epidermal growth factor receptor (EGFR).
Febrile neutropenia: Febrile neutropenia is a serious medical condition characterized by fever and a significant reduction in neutrophil count, often occurring in patients undergoing chemotherapy. It requires prompt medical attention due to the high risk of infection.
HPV Vaccine: The HPV vaccine is a preventive measure against infection by the human papillomavirus (HPV), a group of viruses that can cause various types of cancer, including cervical, anal, and oropharyngeal cancers. The vaccine works by stimulating the body's immune system to produce antibodies that recognize and neutralize the HPV virus, thereby reducing the risk of infection and subsequent development of HPV-related cancers.
Ibrutinib: Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of certain types of cancer, primarily B-cell malignancies. It interferes with cellular signaling pathways, leading to the death of malignant B-cells.
IFNs: IFNs, or interferons, are a group of signaling proteins produced by host cells in response to the presence of pathogens such as viruses, bacteria, and parasites. These proteins play a crucial role in the body's innate immune response by triggering the activation of various defense mechanisms against infectious agents.
ILs: ILs, or Interleukins, are a group of signaling proteins and glycoproteins that are primarily produced by white blood cells and play a crucial role in the regulation and coordination of the immune response within the context of biological response modifiers.
Imbruvica: Imbruvica (generic name: ibrutinib) is an oral medication used to treat various types of cancer by inhibiting Bruton's tyrosine kinase (BTK). It is primarily used in the treatment of certain lymphomas and leukemias.
Imfinzi: Imfinzi is a monoclonal antibody used as an immunotherapy to treat certain types of cancer. It targets and inhibits PD-L1 to help the immune system detect and fight cancer cells.
Immune Checkpoint Inhibitors: Immune checkpoint inhibitors are a class of drugs that work by blocking certain proteins, known as immune checkpoints, that act as 'brakes' on the immune system. By releasing these brakes, immune checkpoint inhibitors allow the body's immune cells to more effectively recognize and attack cancer cells.
Immune System: The immune system is a complex network of cells, tissues, and organs that work together to defend the body against infections, diseases, and foreign invaders. It plays a crucial role in maintaining health and well-being by recognizing and eliminating threats, while also regulating the body's response to various stimuli.
Immunotherapy: Immunotherapy is a type of biological therapy that harnesses the power of the body's immune system to fight diseases, particularly cancer. It works by stimulating or suppressing the immune system to recognize and attack abnormal cells more effectively.
Infusion Reactions: Infusion reactions are adverse events that can occur during the administration of certain medications, particularly biologics, monoclonal antibodies, and biosimilar drugs. These reactions are typically triggered by the body's immune response to the foreign proteins or molecules present in the infused medication.
Interferons: Interferons are a group of signaling proteins released by host cells in response to the presence of pathogens, such as viruses, bacteria, and parasites. They act as important mediators of the innate immune response, playing a crucial role in the body's defense against infections and the regulation of the immune system.
Interleukins: Interleukins are a group of cytokines, or signaling proteins, that are primarily secreted by white blood cells and play a crucial role in regulating immune and inflammatory responses in the body. They act as chemical messengers, facilitating communication between different cell types and coordinating the complex network of the immune system.
Ipilimumab: Ipilimumab is a monoclonal antibody that acts as an immune checkpoint inhibitor, specifically targeting the CTLA-4 receptor on T cells. It is used in the treatment of various types of cancer, including melanoma, by enhancing the body's immune response against tumor cells.
Keytruda: Keytruda is a monoclonal antibody used as an immune checkpoint inhibitor in cancer therapy. It blocks the PD-1 receptor, enhancing the body's immune response against tumor cells.
MAbs: mAbs, or monoclonal antibodies, are laboratory-produced molecules that mimic the immune system's ability to bind to specific targets, such as proteins on the surface of cells. These targeted therapies are designed to recognize and attach to unique antigens, allowing them to deliver a specific therapeutic effect.
Mast cells: Mast cells are a type of white blood cell that play a crucial role in the immune system by releasing histamine and other chemicals during inflammatory and allergic reactions. They are found in connective tissues throughout the body, particularly near blood vessels and nerves.
Monoclonal antibodies: Monoclonal antibodies are laboratory-made molecules that can bind to specific targets, such as antigens on cancer cells. They are used in various therapies, including for cancer and autoimmune diseases.
Monoclonal Antibodies: Monoclonal antibodies are laboratory-produced immune system proteins that are designed to target specific antigens or molecules. They are created by cloning a unique white blood cell, allowing for the mass production of a single, highly specialized antibody that can recognize and bind to a particular target.
Natural Killer Cells: Natural killer (NK) cells are a type of cytotoxic lymphocyte that play a crucial role in the body's innate immune response. They are able to recognize and destroy infected, stressed, or cancerous cells without prior sensitization, making them an important component of the Biologic Response Modifiers.
Neutropenia: Neutropenia is a condition characterized by an abnormally low number of neutrophils, a type of white blood cell that plays a crucial role in the body's immune response. This reduction in neutrophil count can increase an individual's susceptibility to infections, making it an important consideration in the context of cancer and its treatments.
Nivolumab: Nivolumab is a monoclonal antibody that acts as an immune checkpoint inhibitor, primarily targeting the programmed cell death-1 (PD-1) receptor on T cells. It is used as a cancer immunotherapy to enhance the body's immune response against tumor cells.
Opdivo: Opdivo (nivolumab) is an immunotherapy drug known as a checkpoint inhibitor used to treat various types of cancer by enhancing the body's immune response against cancer cells.
PD-1 Inhibitors: PD-1 inhibitors are a class of drugs that block the programmed cell death protein 1 (PD-1) pathway, enhancing the immune system's ability to attack cancer cells. They are a type of immune checkpoint inhibitor used in cancer immunotherapy.
Pembrolizumab: Pembrolizumab is a monoclonal antibody that acts as an immune checkpoint inhibitor, specifically targeting the programmed cell death-1 (PD-1) receptor. It is used in the treatment of various types of cancer by enhancing the body's immune response against cancer cells.
Pneumonitis: Pneumonitis is a general term that refers to inflammation of the lungs, often caused by an immune response or exposure to irritants. It is a key concept in the context of both Biologic Response Modifiers and Potassium Channel Blockers, as these treatments can potentially induce this condition.
Rituxan: Rituxan is a monoclonal antibody used to treat certain autoimmune diseases and types of cancer, particularly non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It works by targeting the CD20 protein on the surface of B cells, leading to their destruction.
Rituximab: Rituximab is a monoclonal antibody used to treat certain autoimmune diseases and types of cancer. It targets the CD20 protein on the surface of B cells, leading to their destruction.
Sipuleucel-T: Sipuleucel-T is an autologous cellular immunotherapy used for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. It is designed to stimulate an immune response against prostate cancer cells by using the patient's own immune cells.
T Cells: T cells, also known as T lymphocytes, are a type of white blood cell that play a central role in the adaptive immune response. They are responsible for cell-mediated immunity, recognizing and responding to specific foreign antigens in the body.
Tarceva: Tarceva (erlotinib) is a targeted cancer therapy drug that inhibits the activity of epidermal growth factor receptor (EGFR) tyrosine kinase. It is primarily used to treat non-small cell lung cancer and pancreatic cancer.
Targeted Therapy: Targeted therapy is a type of cancer treatment that targets specific molecular changes or pathways that are unique to cancer cells, in contrast to traditional chemotherapy which affects both cancer cells and healthy cells. These targeted therapies aim to selectively disrupt the growth and survival of cancer cells while minimizing harm to normal cells.
Tecentriq: Tecentriq is a monoclonal antibody that blocks the PD-L1 protein, helping the immune system to detect and attack cancer cells. It is used in the treatment of various cancers including non-small cell lung cancer and urothelial carcinoma.
Tyrosine Factor/Growth Factor Inhibitors: Tyrosine kinase inhibitors (TKIs) are a class of drugs that block the action of enzymes called tyrosine kinases, which play a role in cancer cell growth and proliferation. Growth factor inhibitors specifically target growth factors or their receptors to prevent cancer cells from receiving signals needed for their survival and division.